<p>股票分拆有时可以成为公司在股票周围制造激动的有效方式。这是公司运营良好的标志，通过分拆降低股票价格，股票可以更容易地被更广泛的投资者群体所接触。这就是为什么股票分拆后股价通常会上涨。</p>
<p>一个股价开始接近 1000 美元的股票是 <strong>礼来</strong>(LLY -3.82%)。其股价接近 1000 美元，公司可能有理由进行股票分拆，或许在今年早些时候就会有。投资者是否应该期待近期会有股票分拆呢？</p>
<h2>礼来 上次进行股票分拆是在 1997 年</h2>
<p>这家医疗保健公司几十年来没有进行股票分拆；它最后一次分拆是在 1997 年进行的 2 比 1 的分拆。虽然那确实是很久以前的事情，可以说礼来并没有必要进行分拆。直到 2018 年，该股票甚至还没有交易超过 100 美元。</p>
<p>但在过去几年里，礼来的股票价格一直在飙升。在五年内，该股票的回报率接近 800%。它已成为全球市值最高的医疗保健股票，并且看起来有望在未来加入万亿美元俱乐部，目前市值约为 8500 亿美元。</p>
<h2>礼来进行股票分拆是否是必然的？</h2>
<p>礼来的股价已经足够高，进行股票分拆是有道理的。但这并不意味着一定会进行分拆。</p>
<p><strong>Chipotle Mexican Grill</strong> 最近进行了股票分拆，其股价在决定进行分拆之前约为 3000 美元。股价远低于这个价格的股票也进行了分拆。去年，礼来的竞争对手 <strong>Novo Nordisk</strong> 进行了 2 比 1 的股票分拆，尽管其股价不到 200 美元。</p>
<p>最终，这取决于管理层。在关于股票分拆的公告实际发生之前，投资者只能猜测是否会发生。</p>
<p>没有保证礼来会在今年或未来五年内分拆其股票。毕竟，股票分拆并不是必要的。即使股价超过 1000 美元，股票仍然有可能升值。拥有零头股份使投资者能够投资于一家企业，无论其股价有多高。</p>
<h2>无论是否进行股票分拆，礼来都是一个很好的买入选择</h2>
<p>有许多投资礼来的理由，包括其有前途的增长前景。由于其有前途的减肥和糖尿病治疗药物 Zepbound 和 Mounjaro，该公司一直在产生令人印象深刻的营收和利润增长。从长远来看，它们有潜力为公司创造数百亿美元的收入，因为礼来已经在火热的抗肥胖治疗市场中确立了自己的领先地位。</p>
<p>由于公司长期业务潜力巨大，尽管估值很高，礼来可能是一个很棒的投资。目前，其市盈率接近 140。</p>
<p>虽然股票分拆可能会带来一些激动，但这并不是投资礼来的理由。无论是否进行股票分拆，该股票都有可能升值。</p>

礼来

<p>礼来（Eli Lilly）的股价接近 1000 美元，引发了关于可能进行股票分拆的猜测。虽然该公司自 1997 年以来没有进行过股票分拆，但股价最近的激增以及未来增长潜力使其成为一项有前途的投资，无论是否进行股票分拆。最终决定在于管理层，目前并不能保证近期会进行股票分拆</p>

<p>Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investors. It's why shares often rally following a stock split.</p>
<div class="lb-trans"><p>股票分拆有时可以成为公司在股票周围制造激动的有效方式。这是公司运营良好的标志，通过分拆降低股票价格，股票可以更容易地被更广泛的投资者群体所接触。这就是为什么股票分拆后股价通常会上涨。</p>
</div><p>One stock that's starting to get up there in price is <strong>Eli Lilly</strong>(LLY -3.82%). Its shares are getting close to $1,000, and there could be a case for the company to deploy a stock split, perhaps as early as this year. Should investors expect one in the near future?</p>
<div class="lb-trans"><p>一个股价开始接近 1000 美元的股票是 <strong>礼来</strong>(LLY -3.82%)。其股价接近 1000 美元，公司可能有理由进行股票分拆，或许在今年早些时候就会有。投资者是否应该期待近期会有股票分拆呢？</p>
</div><h2>Eli Lilly last did a stock split in 1997</h2>
<div class="lb-trans"><h2>礼来 上次进行股票分拆是在 1997 年</h2>
</div><p>The healthcare company hasn't done a stock split in decades; its last one was a 2-for-1 back in 1997. While that's definitely a long time ago, there arguably hasn't been the <em>need</em> for Eli Lilly to do one. Until 2018, the stock wasn't even trading above $100.</p>
<div class="lb-trans"><p>这家医疗保健公司几十年来没有进行股票分拆；它最后一次分拆是在 1997 年进行的 2 比 1 的分拆。虽然那确实是很久以前的事情，可以说礼来并没有必要进行分拆。直到 2018 年，该股票甚至还没有交易超过 100 美元。</p>
</div><p>But in the past few years, shares of Eli Lilly have been taking off. In five years, the stock has generated returns of nearly 800%. It has become the most valuable healthcare stock in the world and looks like it's on track to join the trillion-dollar club in the future with its market cap currently around $850 billion.</p>
<div class="lb-trans"><p>但在过去几年里，礼来的股票价格一直在飙升。在五年内，该股票的回报率接近 800%。它已成为全球市值最高的医疗保健股票，并且看起来有望在未来加入万亿美元俱乐部，目前市值约为 8500 亿美元。</p>
</div><h2>Is a stock split inevitable for Eli Lilly?</h2>
<div class="lb-trans"><h2>礼来进行股票分拆是否是必然的？</h2>
</div><p>Eli Lilly's stock price is high enough that doing a stock split would make sense. But that doesn't mean one is coming.</p>
<div class="lb-trans"><p>礼来的股价已经足够高，进行股票分拆是有道理的。但这并不意味着一定会进行分拆。</p>
</div><p><strong>Chipotle Mexican Grill</strong> recently did a stock split, and its share price was around $3,000 before it decided to do so. Stocks at much lower prices have done splits, as well. Last year, Eli Lilly's rival <strong>Novo Nordisk</strong> deployed a 2-for-1 stock split even though its share price was less than $200.</p>
<div class="lb-trans"><p><strong>Chipotle Mexican Grill</strong> 最近进行了股票分拆，其股价在决定进行分拆之前约为 3000 美元。股价远低于这个价格的股票也进行了分拆。去年，礼来的竞争对手 <strong>Novo Nordisk</strong> 进行了 2 比 1 的股票分拆，尽管其股价不到 200 美元。</p>
</div><p>Ultimately, it comes down to management. Until an announcement about a stock split actually takes place, investors can only speculate about whether it will or won't happen.</p>
<div class="lb-trans"><p>最终，这取决于管理层。在关于股票分拆的公告实际发生之前，投资者只能猜测是否会发生。</p>
</div><p>There are no guarantees that Eli Lilly will split its shares this year or even five years from now. Stock splits aren't a necessity, after all. A stock can rise in value even if its share price is north of $1,000. Owning fractional shares makes it possible for investors to invest in a business regardless of how high its stock price is.</p>
<div class="lb-trans"><p>没有保证礼来会在今年或未来五年内分拆其股票。毕竟，股票分拆并不是必要的。即使股价超过 1000 美元，股票仍然有可能升值。拥有零头股份使投资者能够投资于一家企业，无论其股价有多高。</p>
</div><h2>Eli Lilly is a great buy whether or not it splits its stock</h2>
<div class="lb-trans"><h2>无论是否进行股票分拆，礼来都是一个很好的买入选择</h2>
</div><p>There are many great reasons to invest in Eli Lilly -- including its promising growth prospects. The company has been generating impressive revenue and profit growth due to Zepbound and Mounjaro, its promising weight loss and diabetes treatments. They have the potential to generate tens of billions in revenue for the company in the long run, as Eli Lilly has established itself as an early leader in the scorching-hot market for anti-obesity treatments.</p>
<div class="lb-trans"><p>有许多投资礼来的理由，包括其有前途的增长前景。由于其有前途的减肥和糖尿病治疗药物 Zepbound 和 Mounjaro，该公司一直在产生令人印象深刻的营收和利润增长。从长远来看，它们有潜力为公司创造数百亿美元的收入，因为礼来已经在火热的抗肥胖治疗市场中确立了自己的领先地位。</p>
</div><p>With so much potential for the business in the long run, Eli Lilly could be a fantastic investment, despite its high valuation. It currently trades at a price-to-earnings multiple of nearly 140.</p>
<div class="lb-trans"><p>由于公司长期业务潜力巨大，尽管估值很高，礼来可能是一个很棒的投资。目前，其市盈率接近 140。</p>
</div><p>While a stock split may generate some excitement, it's not a reason to invest in Eli Lilly. The stock is likely to rise in value regardless of whether it splits its shares or not.</p>
<div class="lb-trans"><p>虽然股票分拆可能会带来一些激动，但这并不是投资礼来的理由。无论是否进行股票分拆，该股票都有可能升值。</p>
</div>

礼来公司会在 2024 年进行股票拆分吗？